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introduction: Coagulation and fibrinolysis remain sparsely addressed with regards to 
acute respiratory distress syndrome (ARDS). We hypothesized that ARDS development 
might be associated with changes in plasma coagulation and fibrinolysis. Our aim was 
to investigate the relationships between ARDS diagnosis and plasma concentrations of 
tissue factor (TF), tissue plasminogen activator (t-PA), and plasminogen activator inhib-
itor-1 (PAI-1) in mechanically ventilated patients at increased risk of developing ARDS.
Materials and methods: We performed an ethically approved prospective observational 
pilot study. Inclusion criteria were patients with PaO2/FiO2 < 300 mmHg admitted to the 
intensive care unit (ICU) for mechanical ventilation for 24 h, or more, because of one or 
more disease conditions associated with increased risk of developing ARDS. Exclusion 
criteria were age below 18 years; cardiac disease. We sampled plasma prospectively 
and compared patients who developed ARDS with those who did not using descriptive 
statistics and chi-square analysis of baseline demographical and clinical data. We also 
analyzed plasma concentrations of TF, t-PA, and PAI-1 at inclusion (T0) and on third (T3) 
and seventh day (T7) of the ICU stay with non-parametric statistics inclusive their sensi-
tivity and specificity associated with the development of ARDS using receiver operating 
characteristic curve analysis. Statistical significance: p < 0.05.
results: Of 24 patients at risk, 6 developed mild ARDS and 4 of each moderate or 
severe ARDS, respectively, 3 ± 2 (mean ± SD) days after inclusion. Median plasma 
concentrations of TF and PAI-1 were significantly higher at T7 in patients with ARDS, 
as compared to non-ARDS. Simultaneously, we found moderate correlations between 
plasma concentrations of TF and PAI-1, TF and PaO2/FiO2, and positive end-expira-
tory pressure and TF. TF plasma concentration was associated with ARDS with 71% 
sensitivity and 100% specificity, a cut off level of 145 pg/ml and AUC 0.78, p = 0.02. 
PAI-1 displayed 64% sensitivity and 100% specificity with a cut off concentration of 
117.5 pg/ml and AUC 0.77, p =  0.02. t-PA did not change significantly during the 
observation time.
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inTrODUcTiOn
Acute respiratory distress syndrome (ARDS) represents a 
severe respiratory failure characterized by hypoxia and non-
hydrostatic pulmonary edema with bilateral opacities on frontal 
chest radiographs. Patients with ARDS require treatment in the 
intensive care unit (ICU) for respiratory support with continu-
ous positive airway pressure (CPAP) or positive end-expiratory 
pressure (PEEP) of 5  cmH2O or higher in combination with 
mechanical ventilation (1–3). Usually, ARDS occurs within 
1 week of a triggering event (4, 5) and might be the result of a 
direct lung injury, as pneumonia, or an indirect lung injury, like 
septic shock (6–8).
Incidence of ARDS displays large geographical differences (9, 
10). A recent worldwide multicenter study showed that 10.4% of 
those admitted to participating ICUs and 23.4% of those requir-
ing mechanical ventilation exhibited ARDS criteria. Hospital 
mortality varied among 34.9, 40.3, and 46.1% for patients with, 
respectively, mild, moderate, and severe ARDS (11). This is 
consistent with mortality rates published by previous investiga-
tors (10, 12). Thus, despite a varying incidence, overall mortality 
from ARDS has not changed substantially during the last decade 
(13, 14). Consequently, identification of patients at risk should 
be prioritized with the aim to diagnose ARDS earlier, as recently 
proposed (15).
Several studies have focused on injury to the lung paren-
chyma, which then causes deteriorated gas exchange in ARDS 
(16–18). In contrast, changes in homeostasis of coagulation and 
fibrinolysis have been sparsely investigated despite that their role 
in the evolution of this disease is beyond doubt. Investigators 
recently described a role in the interaction between lung inflam-
mation and the coagulation and the fibrinolytic systems for the 
commencement of ARDS (19, 20).
Inflammation modulates blood coagulation by activat-
ing C-reactive protein, which stimulates monocytes and 
alveolar macrophages to generate tissue factor (TF) (5, 21), and 
endothelial cells to produce plasminogen activator inhibitor-1 
(PAI-1) (22). The combined effects can lead to disseminated 
intravascular coagulation (DIC) including formation of intra-
vascular micro-thrombi and intra-alveolar fibrin deposits (5, 
22–24), subsequently increasing both dead-space ventilation and 
intrapulmonary shunting, both characteristic features of ARDS 
(23). Consequently, we speculated that the circulatory level of TF, 
and the balance between inhibitors and activators of fibrinolysis, 
could be of help for the diagnosing of ARDS (21).
In mechanically ventilated patients, whom we considered to 
be at increased risk of developing ARDS, we aimed to perform 
a pilot study to explore whether associations exist between 
diagnosis of ARDS and the plasma concentration of TF as the 
primary endpoint, and ARDS and plasma levels of PAI-1 and 
tissue plasminogen activator (t-PA), respectively, as secondary 
endpoints.
MaTerials anD MeThODs
Patients eligible for the study
Between November 2014 and February 2015, we transferred 33 
patients to the ICU of Pauls Stradins Clinical University Hospital 
(PSCU), Riga, Latvia, for mechanical ventilation because we 
considered them to be at increased risk of developing ARDS. 
After the Medical Ethics Committee of PSCU had approved the 
study protocol and the informed consent form (No. 18204-5 
L), we screened the patients for suitability to participate in a 
prospective observational pilot study of the influence of plasma 
coagulation and fibrinolysis on the emergence of ARDS. We 
obtained informed consent from each one’s legal guardian prior 
to inclusion for those who were eligible for participation in 
the study.
According to their disease conditions, the patients were 
treated either with non-invasive pressure-controlled mechanical 
ventilation (NIV), or endotracheal intubation and mechanical 
ventilation with CPAP ≥5  cmH2O, or PEEP ≥5  cmH2O over 
24 h or more using Servo-I ventilators (Maquet Getinge, Group, 
Rastatt, Germany). The patients received antibiotics, as required, 
based on the results of microbiological cultures and antibiotic 
resistance testing.
inclusion criteria
We included patients with PaO2/FiO2 < 300 mmHg and with an 
increased risk of developing ARDS (23) because of one or more 
ARDS predisposing conditions causing either direct or indirect 
lung injury. The former included pneumonia or aspiration of 
gastric contents into the airways; the latter comprised of sepsis, 
acute pancreatitis, DIC, burns, drug overdose or trauma with 
circulatory shock, and massive blood transfusions, as outlined 
by previous investigators (23). The patients did not fulfill all the 
required ARDS criteria at the time of inclusion (2). Those who 
fulfilled ARDS criteria within 1  week of the stay in ICU were 
randomized to an ARDS group, the others to a non-ARDS group.
We divided those who fulfilled the clinical, radiological, 
and cardiologic criteria of ARDS into mild, moderate, or 
severe ARDS with the characteristics listed below. Mild ARDS: 
200 mmHg < PaO2/FiO2 ≤ 300 mmHg, CPAP or PEEP ≥5 cmH2O; 
moderate ARDS: 100 mmHg < PaO2/FiO2 ≤ 200 mmHg, PEEP 
≥5 cmH2O; and severe ARDS: PaO2/FiO2 ≤ 100 mmHg, PEEP 
≥5 cmH2O, according to the definition (2).
conclusion: This pilot study showed that increased plasma concentrations of TF and 
PAI-1 might support ARDS diagnoses in mechanically ventilated patients after 7 days 
in ICU.
Keywords: acute respiratory distress syndrome, lung injury, plasminogen activator inhibitor-1, tissue factor, tissue 
plasminogen activator, ventilator-associated lung injury
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exclusion criteria
We excluded patients below 18  years of age, patients receiving 
mechanical ventilation with no ARDS predisposing condition, 
patients not fulfilling the study protocol, and patients from whom 
we did not get consent for participation. We also excluded patients 
after transthoracic echocardiography (ECHO) displaying ejec-
tion fraction (EF) <50% and right ventricular systolic pressure 
>35–40 mmHg, and with a pulmonary artery occlusion pressure 
>18 mmHg, as measured if a Swan Ganz catheter was in place.
study Protocol
We determined plasma concentrations of TF, t-PA, and PAI-1 at 
enrollment (T0) and on the third day (T3) and the seventh day 
(T7) of the ICU stay. Moreover, we noticed ventilator settings 
including FiO2, tidal volume, airway plateau pressure, and PEEP-
levels that were titrated by means of the transpulmonary pres-
sure–volume curve displayed on the Servo-I ventilator, and the 
resulting readings of PaO2/FiO2 and lung mechanical parameters 
from every subject at the time of collection of plasma samples. 
We also recorded number of days on mechanical ventilation, 
ventilator-free days at day 30 of the stay in ICU, and the 30-day 
mortality rate.
We observed the patients in ICU for 1  week and compared 
plasma concentrations of coagulation and fibrinolysis biomark-
ers between those who developed ARDS and those who did not 
develop the disease (non-ARDS), as based on recent criteria (2). 
Demographic and clinical data and direct and indirect ARDS risk 
factors were retrieved from the medical records of the patients. 
The severity of disease was scored at inclusion using the sequential 
organ failure assessment (SOFA) and the acute physiology and 
chronic health evaluation (APACHE II) scores. In addition, we 
calculated lung injury prediction score (LIPS) for every patient at 
the day of inclusion (T0).
Determination of Biomarkers of 
coagulation and Fibrinolysis
We collected blood from a peripheral vein into heparin tubes 
that we cool centrifuged (ELMI CM-6MT®, USA) for 5 min at 
3,000 × g. The plasma supernatant was removed from the spun 
samples and frozen at −70°C until the time of analysis. Human 
TF (CD264) with a normal range of from 12.5 to 400 pg/ml was 
quantitatively assessed by means of an enzyme-linked immuno-
sorbent assay (ELISA) test (Abcam®, UK). Fibrinolysis markers, 
t-PA (normal range 15.6–1,000 pg/ml), and PAI-1 (normal range 
78–5,000 pg/ml) were analyzed with the same method using the 
platinum ELISA kit (eBioscience®, USA).
In parallel, we analyzed standard coagulation tests (SCT) 
such as prothrombin index (PI), international normalized ratio 
(INR), and fibrinogen plasma concentration, as well as platelet 
count (PLT), which was analyzed by means of a Beckman Coulter 
LH 750 Hematology Analyzer (Beckman Coulter International 
SA, Switzerland). Coulter LH 750 uses impedance technology to 
measure PLT count (normal range 150–450 × 109/l). Fibrinogen 
plasma concentration was analyzed in citrated plasma (Multifibren 
U reagent, Siemens Healthcare Diagnostics, USA). The reference 
value is 1.8–3.6 g/l. PI was analyzed using a prothrombin com-
plex assay (Lyophilized Dade® and Innovin® reagent, Siemens 
Healthcare Diagnostics, USA). PI normal range is 70–120%. 
APTT was analyzed in citrated human plasma (Pathrombin*SL 
reagent, Siemens Healthcare Diagnostics, USA). APTT normal 
range is 26–36 s.
statistical analysis and sample size 
calculations
Statistical analyses were performed using the SPSS Statistics 
(Chicago, IL, USA, Version 20). We compared ARDS patients 
and non-ARDS patients and survivors and non-survivors of the 
disease. Data distribution was assessed using Shapiro–Wilk test 
or Kolmogorov–Smirnov test, as appropriate. We used descriptive 
statistics for analysis of baseline demographics and clinical data, 
and Chi-square or Mann–Whitney rank sum test to compare the 
difference between groups. If the F value was greater than criti-
cal, repeated measures ANOVA was followed by Holm–Sidak’s 
post hoc test for pairwise multiple comparisons to check for intra-
group differences. For non-normally distributed data, the results 
were presented as boxes with median and interquartile range 
(IQR; 25th–75th percentile), including vertical error bars for the 
10 and 90% lowest and highest values, respectively. Correlations 
were presented as Spearman’s rs (25). We performed receiver 
operating characteristic (ROC) curve analysis of coagulation and 
fibrinolytic biomarkers including calculations of area under the 
curve (AUC) for TF and PAI-1 to demonstrate their efficiency in 
supporting ARDS diagnosis. Spearman’s correlation coefficient 
also was calculated to analyze the relationships between coagula-
tion/fibrinolysis markers and ventilation parameters. Statistical 
significance was defined as p < 0.05. When required, we calculated 
sample sizes needed to reach significant differences (p < 0.05) in 
plasma concentrations of TF, PAI-1, and t-PA at a power of 80% 
between the ARDS group and the non-ARDS group.
resUlTs
clinical course
As depicted in Figure 1, we assessed 33 mechanically ventilated 
patients, considered to be at risk of developing ARDS, for suit-
ability to the study. We excluded seven patients who died before 
they fulfilled all the requirements of the study protocol, and two 
patients from whom we did not get consent for participation.
Table  1 displays demographic characteristics and clinical 
variables of 24 patients (21 men and 3 women) fulfilling inclu-
sion criteria and all requirements of the protocol encompassing 
comorbidities, conditions predisposing for ARDS, severity 
scores, and standard coagulation variables. Pneumonia (46%) 
was the most common underlying disease. However, neither 
ARDS nor non-ARDS patients displayed significant intergroup 
differences with regard to demographic data, comorbidities, or 
predisposing conditions. Patients diagnosed with ARDS had 
significantly higher baseline values of SOFA, APACHE II, and 
LIPS scores. Moreover, the ARDS group showed significant 
differences in systemic coagulation (elevated INR, lower PLT, 
and fibrinogen plasma levels), but no clinical signs of DIC. The 
mean time for developing ARDS was 3 ± 2 days after inclusion. 
Six patients developed mild ARDS, whereas moderate or severe 
ARDS occurred within 1 week of the inclusion in four patients 
FigUre 1 | Mechanically ventilated patients considered for eligibility to a prospective pilot study. Twenty-four patients fulfilled the study protocol. SCT, 
standard coagulation tests; APACHE II, acute physiology and chronic health evaluation II; SOFA, sequential organ failure assessment; LIPS, lung injury prediction 
score; ARDS, acute respiratory distress syndrome.
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each, thus constituting in all 58% of the population at risk. Days 
in ICU and ventilator-free days at day 30 displayed no intergroup 
differences. Total hospital mortality and mortality at day 30, 
reached 25%, but displayed no significant differences between 
the groups.
Table 2 displays ventilation parameters and PaO2/FiO2 at T0, 
T3, and T7. Tidal volumes were significantly smaller at T0 and T7 in 
ARDS patients, as compared to the non-ARDS group. Despite that 
plateau pressures were significantly higher in the ARDS group at 
T3 and T7, and PEEP also was significantly raised at the latter time 
point, these ventilator settings did not prevent a significant fall in 
PaO2/FiO2 in comparison with the non-ARDS group.
comparison of coagulation and 
Fibrinolysis in arDs vs. non-arDs 
Patients
Plasma concentrations of TF (Figure  2A) remained within 
normal range with no significant difference between ARDS 
and non-ARDS group at T0 (p =  0.229), but displayed marked 
intergroup differences at T3 (p = 0.043) and T7 (p = 0.022). The 
ARDS group also showed intragroup differences in TF plasma 
concentrations between the highest value at T7 in comparison 
with those at T0 and T3, respectively (p < 0.001). In contrast, we 
found no significant intragroup differences in the plasma levels 
of TF in the non-ARDS group.
Plasma levels of PAI-1 (Figure  2B) showed no intergroup 
differences at T0 and T3, but increased at T7 in the ARDS group, 
as compared with non-ARDS group (p =  0.026). Plasma con-
centration of PAI-1 at T7 in the ARDS group was also increased 
in comparison with intragroup values at T0 (p = 0.016) and T3 
(p = 0.017), but not no significant difference was found between the 
latter concentrations. Plasma levels of t-PA fell at T3 (Figure 2C), 
but we noticed no significant differences within or between the 
groups. At T3, plasma concentration of t-PA was 295 ± 85 pg/ml 
(mean ± SD) in ARDS survivors vs. 516 ± 160 pg/ml in ARDS 
non-survivors, but the difference did not reach significance due 
to low sample size.
We found significant correlations between plasma concentra-
tions of TF and PAI-1 (r = 0.53; p = 0.008), TF and PaO2/FiO2 
TaBle 2 | Ventilation variables at inclusion (T0) and at the third (T3) and 
seventh (T7) day of icU stay in arDs and non-arDs patients.
Ventilation 
settings
arDs, n = 14 non-arDs, n = 10 p-Value
Median iQr Median iQr
Tidal volume, l/min
T0 8.6 7.1–9.2 10.1 8.8–11.3 0.01
T3 7.8 6.7–8.9 9.6 8.9–10.1 NS
T7 7.1 6.6–7.7 8.7 8.3–9.0 0.002
Plateau pressure, cmh2O
T0 29 22–35 24 21–27 NS
T3 30 23–36 26 22–30 0.002
T7 27 21–34 25 20–31 0.012
PaO2/FiO2
T0 158.5 42–282 183.2 74–348 NS
T3 193.5 94–362 234 58–358 NS
T7 179.5 57–292 284 80–356 0.03
PeeP, cmh2O
T0 7 5–11 5 3–7 NS
T3 7 5–13 5 4–7 NS
T7 7 5–13 5 2–6 0.006
Data are presented as median and interquartile range (IQR).
ARDS, acute respiratory distress syndrome; cmH2O, centimeter of water; FiO2, fraction 
of inspired oxygen; kg, kilograms; ml, milliliters; n, number of patients; PaO2, partial 
pressure of oxygen in blood; PEEP, positive end-expiratory pressure; NS, not significant.
TaBle 1 | Baseline demographic characteristics, arDs predisposing factors, and mortality.
Demographic data Totally, n = 24 arDs, n = 14 non-arDs, n = 10 p-Value
Age, years 54 ± 17 55 ± 15 53 ± 19 0.7
Women, n (%) 3 (12) 2 (14) 1 (10) 0.8
BMI 26.4 ± 4.6 24.7 ± 2.8 27.2 ± 3.2 0.4
comorbidities
Hypertension, n (%) 7 (29) 4 (29) 3 (30) 0.1
Diabetes mellitus, n (%) 4 (17) 2 (14) 2 (20) 0.6
COPD, n (%) 3 (12) 1 (7) 2 (20) 0.4
conditions predisposing for arDs
Pneumonia, n (%) 11 (46) 6 (42) 5 (50) 0.7
Sepsis, n (%) 7 (29) 4 (29) 3 (30) 0.9
Pancreatitis, n (%) 5 (21) 4 (29) 1 (10) 0.3
Massive transfusions, n (%) 1 (4) 0 1 (10) 0.2
severity scores
SOFA, median (range) 4 (3.4–6.1) 5 (4.6–7.2) 3 (2.1– 4.9) 0.04
APACHE II, median (range) 23 (19–28) 25 (22–28) 21 (19–24) 0.03
LIPS median (range) 5.8 (0.3–13) 8.1 (3–13) 4.9 (0.3–9) 0.01
coagulation status
INR 1.18 ± 0.4 1.2 ± 0.6 1.12 ± 0.15 0.03
PLT (109/l) 172 ± 56 136 ± 47 213 ± 31 0.003
Fibrinogen (mg/dl) 283 ± 71 261 ± 96 312 ± 63 0.02
icU stay and mechanical ventilation
ICU days, n 12 ± 5 14 ± 7 11 ± 4 0.7
Ventilator-free days, n 5 ± 3 4 ± 2 7 ± 4 0.4
Mortality
Hospital, n (%) 6 (25) 4 (29) 2 (20) 0.1
30-day, n (%) 6 (25) 4 (29) 2 (20) 0.1
Data are presented as mean ± SD, number (n), or median (range).
APACHE II, chronic health evaluation score; ARDS, acute respiratory distress syndrome; BMI, body mass index; ICU, intensive care unit; INR, international normalized ratio; LIPS, 
lung injury prediction score; n, number of patients; PLT, platelets; %, percent; range, lowest and highest value; SOFA, sequential organ failure assessment score.
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(r = −0.65; p = 0.001), and PEEP and TF (r = 0.55; p = 0.005) at 
time T7, as depicted in Figures 3A–C.
In ARDS patients, a ROC analysis (Figure 4) showed 71% sen-
sitivity and 100% specificity for an association with TF at T7 with a 
cut off value of 145 pg/ml [AUC 0.782; p = 0.021; 95% confidence 
interval (95%CI): 0.586–0.979]. We also found an association 
with PAI-1 determined at the same time point with a sensitivity 
and specificity of 64 and 100%, respectively, with a cut off value of 
117.5 pg/ml (AUC 0.775; p = 0.024, 95%CI: 0.584–0.966).
DiscUssiOn
In this prospective pilot study, 14 out of total 24 patients con-
sidered to be at increased risk of ARDS, developed the disease 
within 7  days of commencement of mechanical ventilation. 
Patients diagnosed with ARDS had significantly higher baseline 
severity scores in comparison with the non-ARDS group, which 
could indicate a worse outcome. However, mortality did not differ 
significantly between groups (Table 1). In the ARDS group, PaO2/
FiO2 reached nadir on the seventh day of the ICU stay, in parallel 
with significant changes in variables of coagulation and fibrinoly-
sis. In patients diagnosed with ARDS, plasma concentrations of 
TF and PAI-1 increased significantly at T7, as compared with the 
non-ARDS group. The observation of increased TF is consistent 
with recent findings in patients with sepsis-induced ARDS (5). 
Therefore, our findings suggest a role for these biomarkers as 
supportive diagnostic tools during the emergence of ARDS.
Development of ARDS in a population at risk depends on both 
genetic predisposition and interaction between several biological 
pathways, including inflammation, coagulation, and fibrinolysis 
(19). We intentionally observed patients in the ICU for 1 week 
FigUre 2 | Plasma concentrations of markers of coagulation and 
fibrinolysis in arDs and non-arDs patients. (a) Plasma concentration 
of tissue factor (TF) vs. time in ARDS group and non-ARDS group. Data 
presented as median and interquartile range with 10th and 90th percentiles 
error bars. T0 is day of enrollment, T3 and T7, the third day and the seventh 
day of ICU stay. *denotes intergroup p = 0.043 at T3 and p = 0.022 at T7. 
#denotes ARDS intragroup p ≤ 0.001 between T7 and T0 and T3, respectively. 
pg/ml, picogram per milliliter; closed circles represent outliers. (B) Plasma 
concentrations of plasminogen activator inhibitor-1 (PAI-1) vs. time in ARDS 
group and non-ARDS group. Data presented as median and interquartile 
range with 10th and 90th percentiles error bars. T0 is day of enrollment, T3 
and T7, the third day and the seventh day of ICU stay.  
*denotes intergroup p = 0.026 at T7. #denotes ARDS intragroup p = 0.016 
between T7 and T0 and p = 0.017 between T7 and T3. pg/ml, picogram per 
milliliter; closed circles represent outliers. (c) Plasma concentration of tissue 
plasminogen activator (t-PA) vs. time in ARDS group and non-ARDS group. 
Data presented as median and interquartile range with 10th and 90th 
percentiles error bars. T0 is day of enrollment, T3 and T7, the third day and the 
seventh day of ICU stay. No significant intergroup or intragroup differences; 
closed circles represent outliers.
(Continued)
FigUre 2 | continued
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after inclusion for biomarker detection. This was inspired by 
observational studies suggesting that the majority of patients are 
identified with ARDS within 72 h of the recognition of risk factors, 
and nearly all within 7 days of hospital stay (22, 25, 26). However, 
in spite of our efforts to keep low tidal volumes and to titrate 
PEEP to a point above the lower inflection of the transpulmonary 
pressure–volume curve, yielding optimal oxygenation, both tidal 
volume and plateau pressure increased significantly at T7, and 
we were not able to prevent PaO2/FiO2 from falling in the ARDS 
group. This is consistent with the derangements in oxygenation 
and lung mechanics in developing ARDS, as reported by other 
researchers (2, 14).
arDs and Biomarkers of coagulation 
and Fibrinolysis
Investigators have focused on different biomarkers of ARDS (3, 
5, 19, 24), but so far, without significant preferences. Protein 
C plasma levels are reduced in patients with severe sepsis (26) 
and in victims of ARDS, due to a greater consumption of this 
anticoagulant and anti-inflammatory protein (19, 20). However, 
when it was discovered that replacement therapy with recom-
binant human activated protein C had no significant effect on 
survival, neither from severe sepsis nor from ARDS, the interest 
in protein C vanished (27, 28). Alterations in plasma coagulation 
and fibrinolysis have not yet been evaluated in view of the latest 
diagnostic criteria of ARDS that define “acute onset” as a condi-
tion developing within 1  week of a known insult, or a new or 
worsening respiratory failure (29).
We included patients during a 1-year period since some of the 
conditions with increased risk of ARDS, like influenza and pneu-
monia have their seasonal peaks. To detect a possible significance 
of plasma concentrations of TF, PAI-1, and t-PA, as diagnostic 
markers, we studied an ICU population, which had increased 
risk of ARDS and required mechanical ventilation for at least 
24 h. Several researchers have suggested a potential association 
between TF and the occurrence of ARDS. TF appears to play a 
pivotal role both in regulating endothelial permeability and in 
activating the external coagulation pathway in severe infections 
(5, 30, 31). Moreover, investigators demonstrated higher plasma 
TF levels in parallel with lower PLTs and higher incidence of DIC 
in patients with ARDS, in whom the primary injury was trauma 
or sepsis (30). Recently, Xue and co-workers found that, patients 
with sepsis-induced ARDS had significantly higher levels of TF 
on the day of admission as compared with non-ARDS patients. 
The AUC for the diagnosis sepsis-induced ARDS was 0.749. 
These investigators concluded that TF is an independent predic-
tor of 30-day mortality in patients with severe sepsis (OR 1.41; 
FigUre 3 | correlations between tissue factor (TF) and plasminogen activator inhibitor-1 (ai-1) and ventilation parameters on the seventh day (T7) of 
icU stay. (a) Relationship between plasma concentrations of TF and PAI-1 in 24 ICU patients. Data presented as Spearman’s correlation coefficient (r) with p-value. 
TF, tissue factor; PAI-1, plasminogen activator inhibitor; pg/ml, picogram per milliliter. (B). Relationship between plasma concentrations of TF and PaO2/FiO2 in 24 
ICU patients. Data presented as Spearman’s correlation coefficient (r) with p-value. PaO2, arterial oxygen partial pressure; FiO2, fraction of inspired oxygen; TF, tissue 
factor; pg/ml, picogram per milliliter. (c) Relationship between plasma concentrations of TF and level of PEEP in 24 ICU patients. Data presented as Spearman’s 
correlation coefficient with p-value. PEEP, positive end-expiratory pressure; cmH2O, centimeter of water; TF, tissue factor; pg/ml, picogram per milliliter.
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95% CI 1.24–1.69) with AUC 0.718 (5). Consistent with the latter 
workers, we showed that TF increased significantly the seventh 
day after inclusion in the ARDS group as compared with non-
ARDS patients (Figure 2A). A ROC curve analysis displayed a 
sensitivity of 71% with AUC of 0.78, p = 0.02, which indicates a 
fair test value in favor of diagnosing ARDS, according to the pub-
lished criteria (2, 5). However, we did not observe any correlation 
between TF and DIC, since none of our patients was diagnosed 
with that condition. In contrast, TF plasma levels correlated 
moderately with ventilation parameters (Figures  3B,C), most 
likely, because of a high proportion of patients with pneumonia 
(42%) in the ARDS group. Therefore, we consider TF to be a tool 
for supporting ARDS diagnosis, but without any predictive value 
since the increase in plasma concentration occurred after 1 week 
of ICU stay.
In the present study, PAI-1 plasma concentration also 
increased significantly in ARDS patients on the seventh day of 
stay in ICU (Figure  2B). The rise in PAI-1 correlated slightly 
with a parallel increase in TF (Figure  3A) and ROC curve 
analysis (Figure 4) revealed a sensitivity of 64% with AUC of 
0.775; p = 0.024, which indicates a somewhat poorer test in favor 
of diagnosing ARDS, as compared with the corresponding test 
of TF. Previous investigators have noticed that ARDS patients 
exhibit early elevation of PAI-1 activity in both plasma and air 
spaces in concert with a decrease in alveolar fibrinolysis (32, 
33). Thus, El Solh and co-workers showed that tracheal aspirate 
PAI-1 antigen levels, sampled 8  h after witnessed aspiration, 
increased by a fivefold in those who progressed to ARDS, as 
compared with those with uncomplicated aspiration pneumo-
nitis (34). The reason for the discrepancy between our results 
and those of the latter researchers, aside from different analytic 
techniques, could be that changes in tracheal aspirate PAI-1 
antigen concentration occurs earlier as compared to the changes 
in plasma concentration (32).
Lately, Sapru and co-workers demonstrated in pediatric 
patients, that increased plasma concentrations of PAI-1, as 
determined the day after diagnosing ARDS, were associated with 
increased mortality and fewer ventilator-free days until day 28 
(24). Furthermore, investigators who showed that plasma con-
centrations of PAI-1 increased from days 0 to 3 after diagnosing 
ARDS, predicted death with an odds ratio of 1.66 (p = 0.006) (20). 
Moreover, a prospective study of 50 patients with ARDS at an 
early stage showed significantly higher PAI-1 levels in those who 
died as compared with those who survived (19). However, we 
FigUre 4 | rOc curves showing sensitivity and specificity of tissue 
factor and plasminogen activator inhibitor-1 for arDs diagnoses on 
the seventh day (T7) of icU stay. ARDS group displaying 71% sensitivity 
and 100% specificity for association with plasma concentration of TF. Cut off 
value: 145 pg/ml; AUC 0.782; p = 0.021; 95%CI: 0.586–0.979. 
Correspondingly, plasma concentration of PAI-1 showed sensitivity and 
specificity of 64 and 100%, respectively, and a cut off value of 117.5 pg/ml; 
AUC 0.775; p = 0.024; 95%CI: 0.584–0.966. AUC, area under the curve; 
95%CI, 95% confidence interval; PAI-1, plasminogen activator inhibitor-1; 
ROC, receiver operating characteristics; TF, tissue factor.
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confirmed none of the latter findings in this pilot study, which 
was underpowered for such investigations.
As an acute-phase protein, the serine protease inhibitor PAI-1 
binds covalently to t-PA, reduces formation of plasmin, and 
impedes fibrinolytic bleeding. Moreover, recent experimental 
studies indicate that PAI-1 also plays a role in upregulating 
inflammation after exposure to lipopolysaccharides or avian flu 
virus in conditions like ARDS (35, 36). However, in the present 
study, when we compared the ARDS group with non-ARDS 
patients, we found no significant differences in t-PA levels during 
the first week after inclusion. Thus, whether t-PA is a predictive 
marker of ARDS is still not concluded, but this hypothesis was not 
supported in the present prospective pilot study.
We admit that our study has several limitations because of 
the small number of patients included. For this reason, we could 
not expect to find significant differences between groups neither 
in ICU stay and mechanical ventilation, nor in mortality rates. 
Despite the fact that we found a lower plasma concentration of 
t-PA at T3 in ARDS survivors in comparison with non-survivors, 
the test had a power of only 60% due to low sample size. However, 
by keeping the ratio between the groups unchanged, an increase 
in sample size to 14 survivors and 6 non-survivors, would give a 
significant difference with a power of 80%. Correspondingly, to 
reach a significant intergroup difference in t-PAI with the same 
power at T7, would require a total sample size of 317 patients. 
Therefore, due to low sample sizes, we were not able to strengthen 
our findings by means of multivariate analysis. Since mean time 
to diagnosing ARDS was on the average 3 days, we also admit 
as a limitation of any predictive role, the fact that most of the 
patients already had ARDS at the time of plasma sampling at T3, 
whereas significant changes in TF and PAI-1 occurred first at T7. 
Nevertheless, our observations indicate a role for TF and PAI-1 
as tools for supporting ARDS diagnosis, although significant 
changes occurred relatively late in the evolution of disease.
We also denote as a weakness of this study that the ARDS 
patients incorporated many serious risk factors and comorbidities 
when admitted to the ICU. Therefore, those who were included 
had different lengths of hospital stays before admission to the 
ICU. However, the prior history was not an issue for evaluation 
in the present study.
According to ARDS definition (2), we should be able to 
identify patients with mild ARDS that potentially correlates with 
a better prognosis. However, besides a low number of patients 
included, we did not follow oxygenation variables often enough 
to be able to evaluate them properly against changes in ventila-
tor settings, or other variables on an hourly basis. For the same 
reason, changes in concentrations of biomarkers that might 
have taken place, between the days of plasma sampling remain 
undiscovered. We also realize that sampling of bronchoalveolar 
lavage fluid, in parallel with the plasma samples, could have 
strengthened the findings, and maybe enabled the discovery of 
changes in biomarkers at an earlier time point.
A limitation is also the course of ARDS development that may 
influence the changes in biomarkers and outcome significantly. 
We included only patients with high risk of developing ARDS, but 
even among them, particularly patients with severe pneumonia 
have a poor prognosis in comparison with victims of multi-trauma 
and/or those undergoing massive blood transfusions. Finally, 
due to limited sample sizes, the findings of this pilot study need 
confirmation in a larger randomized controlled multicenter trial.
cOnclUsiOn
Fourteen of the 24 patients on mechanical ventilation whom we 
suspected to be at increased risk, developed ARDS on the average 
3 days after admission to the ICU. Activation of the coagulation 
and the fibrinolytic systems in terms of increased plasma levels of 
TF and PAI-1 occurred on the seventh day of ICU stay in patients 
diagnosed with ARDS, thus indicating a supportive diagnostic 
role for these biomarkers. Our findings need confirmation in a 
larger randomized controlled multicenter trial.
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